Evidence map›Paper›PMID 41015624›Full record

ArticleAnnals of surgical oncology2026

Repeat Cytoreductive Surgery for Colorectal Cancer Metastatic to the Peritoneal Cavity.

Paula Marincola Smith, Jessica J Lie, Ashlee Seldomridge, Norman J Galbraith, Jaganmurugan Ramamurthy, Yun Song, Beth A Helmink, Paul F Mansfield, Keith F Fournier, Michael G White

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Paula Marincola SmithDepartment of Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA. psmith7@mdanderson.org.ORCID http://orcid.org/0000-0001-9550-6626
Jessica J LieDepartment of Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ashlee SeldomridgeDepartment of Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Norman J GalbraithDepartment of Colorectal Surgery, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jaganmurugan RamamurthyDepartment of Colorectal Surgery, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yun SongDepartment of Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Beth A HelminkDepartment of Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Paul F MansfieldDepartment of Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Keith F FournierDepartment of Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael G WhiteDepartment of Colorectal Surgery, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

CTSA K12 Program at The University of Texas Health Science Center at HoustonK12TR004908 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Charles C Miller, JON E. TYSON · 2024 to 2026
$2.9M
NCATS NIH HHS K12 TR004908NCI NIH HHS K12TR004908
6 · The paper itself

Abstract

introductionColorectal cancer (CRC) is a leading cause of cancer-related death worldwide. 5-15% of CRC patients develop peritoneal metastases (PM), and those with PM have poor prognosis. For patients with new CRC-related PM, surgical treatment, including cytoreductive surgery (CRS) with/without hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to improve survival compared with systemic therapy alone; however, little is known about the benefits of re-do CRS for recurrent PM.

methodsAll CRC patients who underwent CRS with/without HIPEC (2008-2023) were retrospectively identified at one major referral center. Clinicodemographic variables were extracted by chart review. Recurrence-free survival (RFS), peritoneal disease-free survival (PDFS), and overall survival (OS) were evaluated using the Kaplan-Meier method.

resultsOverall, 139 patients underwent one or more CRS procedures and were included in this study, with 56 patients undergoing two CRS procedures and 15 undergoing three or more CRS procedures. Median age was 50 years. 113 (81%) patients experienced recurrence after their first CRS (CRS1) compared with 45 (80%) after the second CRS (CRS2) and 13 (87%) after the third CRS (CRS3), with most patients experiencing peritoneal recurrence (73% after CRS1, 75% after CRS2, 67% after CRS3). RFS and PDFS were similar after CRS1 and CRS2 (p = 0.17 and p = 0.34, respectively). Patients who underwent a 'targeted' rather than 'complete' index CRS experienced shortened PDFS (p < 0.01) but equivalent OS (p = 0.84).

conclusionsRFS/PDFS following CRS1 is largely predictive of RFS/PDFS after CRS2, with a small number of patients experiencing long-term RFS/PDFS after CRS2. Re-do CRS should be considered for appropriately selected patients with CRC-related PM.

Indexed as

Colorectal NeoplasmsCytoreduction Surgical ProceduresHyperthermic Intraperitoneal ChemotherapyNeoplasm Recurrence, LocalPeritoneal NeoplasmsAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisReoperationRetrospective StudiesSurvival Rate

Identifiers

PMID41015624
PMCPMC12550768

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.